| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| ln Vitro |
Mepivacaine hydrochloride inhibits sodium influx and membrane depolarization by binding to particular voltage-gated sodium channels in the membranes of neuronal cells. This leads to reversible sensory loss and a blockage in the beginning and conduction of nerve impulses. This medication acts more quickly and lasts for a moderate amount of time when compared to other local anesthetics [2]. Compared to procaine, mepivacaine hydrochloride acts more quickly at first and for a longer amount of time in the middle [3]. Preferential usage-dependent blockage of Na(v)1.8 is demonstrated by mepivacaine hydrochloride, while TTX Na(+) channels are preferred by S(-)-bupivacaine [4].
|
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Medication Use During Lactation There is currently no information regarding the use of mepivacaine during lactation. Given the low levels of other local anesthetics in breast milk, a single dose of mepivacaine during lactation is unlikely to have adverse effects on breastfed infants. However, other medications may be preferred, especially when breastfeeding newborns or preterm infants. Mepivacaine administered to mothers as a local anesthetic during labor has been reported to affect initial breastfeeding behavior in some infants, but not weight gain in the first 5 days postpartum. Although research on mepivacaine is limited, it appears that with good breastfeeding support, epidural local anesthetics, whether or not combined with fentanyl or its derivatives, have little or no adverse effects on breastfeeding success. Labor analgesia may delay the onset of lactation. More research is needed to clarify the impact of mepivacaine use during labor on breastfeeding outcomes. ◉ Effects on Breastfed Infants As of the revision date, no relevant published information was found. ◉ Effects on Lactation and Breast Milk A study compared the effects of epidural analgesia using mepivacaine, bupivacaine, and lidocaine during normal labor. The results showed no difference in weight change among the three groups of breastfed infants in the first five days postpartum. Overall weight gain was within the normal range in all groups. Of the six infants who received mepivacaine pudendal nerve block within one hour before delivery, four started breastfeeding later and had fewer initial milk volumes than 10 infants who did not receive anesthesia during delivery. The long-term consequences of these differences have not been reported. A national survey of women and their infants from late pregnancy to 12 months postpartum compared the time to lactroogenesis II in mothers who received and did not receive analgesia during labor. Drug categories included: spinal or epidural anesthesia alone, spinal or epidural anesthesia combined with other drugs, and other analgesics alone. Women who received any type of labor analgesia were approximately twice as likely to experience a delay in the second stage of lactation (>72 hours) compared to women who did not receive labor analgesia. |
| References | |
| Additional Infomation |
Mepivacaine hydrochloride is the hydrochloride salt of mepivacaine and is used as a local anesthetic. It is a piperidine carboxamide compound with local anesthetic effects. Its function is related to that of mepivacaine. Mepivacaine hydrochloride is the hydrochloride form of mepivacaine, an amide derivative with local anesthetic properties. At the injection site, mepivacaine hydrochloride acts by binding to specific sodium ion channels on the neuronal cell membrane, thereby inhibiting sodium ion influx. This leads to nerve impulse conduction blockade, ultimately resulting in loss of sensation. Mepivacaine is a local anesthetic with a chemical structure related to bupivacaine but pharmacologically related to lidocaine. It is suitable for infiltration anesthesia, nerve blocks, and epidural anesthesia. Mepivacaine is only effective when used locally in large doses and therefore should not be used via this route. (Excerpt from AMA Drug Evaluation, 1994, p. 168) See also: mepivacaine (with active fraction); levonorepinephrine; mepivacaine hydrochloride (component).
|
| Molecular Formula |
C15H23CLN2O
|
|---|---|
| Molecular Weight |
282.8089
|
| Exact Mass |
282.149
|
| CAS # |
1722-62-9
|
| Related CAS # |
(+)-Mepivacaine;24358-84-7;Mepivacaine;96-88-8
|
| PubChem CID |
66070
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
383.1ºC at 760 mmHg
|
| Melting Point |
255-257ºC (dec.)
|
| Flash Point |
185.5ºC
|
| Vapour Pressure |
4.52E-06mmHg at 25°C
|
| LogP |
3.539
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
282
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RETIMRUQNCDCQB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H22N2O.ClH/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3;/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18);1H
|
| Chemical Name |
N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~353.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (353.59 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5359 mL | 17.6797 mL | 35.3594 mL | |
| 5 mM | 0.7072 mL | 3.5359 mL | 7.0719 mL | |
| 10 mM | 0.3536 mL | 1.7680 mL | 3.5359 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04561921 | Unknown status | Drug: Magnesium sulfate Drug: Mepivacaine-Levonordefrin Hydrochloride |
Success of Inferior Alveolar Nerve Block | Cairo University | 2020-10-22 | Not Applicable |
| NCT03725579 | Unknown status | Drug: mepivicane hydrochloride Drug: articane hydrochloride |
Symptomatic Irreversible Pulpitis | Cairo University | 2018-09-15 | Phase 2 Phase 3 |
| NCT04822415 | Completed | Drug: Mepivacaine Drug: Articaine |
Symptomatic Irreversible Pulpitis | Cairo University | 2014-12 | Not Applicable |
| NCT04947267 | Completed | Drug: 3% Mepivacaine Hydrochloride Drug: 2% Mepivacaine with 1:100,000 epinephrine |
LOCAL ANESTHESIA | Afshan Amjad Ali | 2018-05-30 | Phase 2 |
| NCT05765682 | Completed | Other: Mepivacaine Spinal Other: Bupivacaine Spinal |
Total Knee Replacement | Medical University of South Carolina | 2023-03-13 | Not Applicable |